Companies Myovant Sciences Ltd.
Myovant Sciences CEO salary & total pay, FY2021: $6.2M
Myovant Sciences (MYOV) CEO salary, fiscal 2021: David Marek was paid a salary of $750,000 and $6,247,509 in total compensation. Free brief. Every figure links to the company’s own filing.
Myovant Sciences Ltd. no longer files a proxy statement; its last pay data is FY2021.
David Marek's complete compensation dossier
A PDF and a CSV sent to your email: David Marek's pay in every fiscal year Myovant Sciences Ltd. reported it, line by line, with David Marek's equity grants and Myovant Sciences Ltd.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $10,276,517FY2020
- $6,247,509FY2021
CEO total pay was $6,247,509 in fiscal 2021, down from $10,276,517 in fiscal 2020.
FY2021: salary $750,000 · bonus $0 · stock awards $2,410,027 · option awards $2,407,333
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Marek | $750,000 | $0 | $2,410,027 | $2,407,333 | $473,000 | $0 | $207,149 | $6,247,509 |
| Principal Executive Officer | ||||||||
| Uneek Mehra | 278,609 | 200,000 | 2,249,996 | 2,283,515 | 142,000 | 0 | 10,752 | 5,164,872 |
| Principal Financial Officer | ||||||||
| Frank Karbe | 212,884 | 251,000 | 1,128,907 | 1,152,197 | 270,000 | 0 | 1,436,149 | 4,451,137 |
| Former Principal Financial and Accounting Officer | ||||||||
| Lauren Merendino | 461,721 | 0 | 1,399,986 | 1,425,545 | 175,000 | 0 | 1,425 | 3,463,677 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2021 total | FY2020 total | FY2019 total | Δ FY2020→2021 |
|---|---|---|---|---|
| David Marek | $6,247,509 | $10,276,517 | — | ↓ −4,029,008 |
| Uneek Mehra | 5,164,872 | — | — | — |
| Frank Karbe | 4,451,137 | 2,989,412 | — | ↑ +1,461,725 |
| Lauren Merendino | 3,463,677 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2021
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| David Marek | Option | 76,606 | 229,821 | 20.54 | — |
| David Marek | RSU | — | 167,307 | — | 2,228,529 |
| David Marek | Option | — | 208,218 | 17.88 | — |
| David Marek | RSU | — | 134,789 | — | 1,795,389 |
| Lauren Merendino | Option | — | 123,300 | 17.88 | — |
| Lauren Merendino | RSU | — | 78,299 | — | 1,042,943 |
| Uneek Mehra | Option | — | 165,192 | 21.83 | — |
| Uneek Mehra | RSU | — | 103,069 | — | 1,372,879 |
Director compensation
No director compensation table is on file for fiscal year 2021.
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $266,200 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Peer group, and who names Myovant Sciences as a peer
Companies that benchmark against MYOV
The list of companies that name MYOV as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Myovant Sciences Ltd. | 2021 | David Marek | $750,000 | $2,410,027 | $2,407,333 | $473,000 | $6,247,509 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2022 | 2022-10-21 | 68,808,308 | 5,909,941 | 407,689 | 91.59% | Passed |
| 2021 | 2021-11-05 | 72,455,802 | 1,191,204 | 92,330 | 98.26% | Passed |
| 2020 | 2020-09-15 | 52,028,047 | 14,146,332 | 751,740 | 77.74% | Passed |
| 2019 | 2019-08-23 | 80,796,510 | 196,867 | 35,456 | 99.76% | Passed |
| 2017 | 2017-08-18 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2022 | 2022-10-21 | 91.59%a |
| 2021 | 2021-11-05 | 98.26%b |
| 2020 | 2020-09-15 | 77.74%c |
a. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total and will have the same effect as "Against" votes.”.
b. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total and will have the same effect as "Against" votes.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total and will have the same effect as "Against" votes.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (9 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, David Marek. DEF 14A, filed 2022-07-28. Section “Executive Compensation” · page 32. As printed: 6,247,509. View filing ↗
- Section 01, Uneek Mehra. DEF 14A, filed 2022-07-28. Section “Executive Compensation” · page 32. As printed: 5,164,872. View filing ↗
- Section 01, Frank Karbe. DEF 14A, filed 2022-07-28. Section “Executive Compensation” · page 32. As printed: 4,451,137. View filing ↗
- Section 01, Lauren Merendino. DEF 14A, filed 2022-07-28. Section “Executive Compensation” · page 32. As printed: 3,463,677. View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-10-21. Item 5.07 · say-on-pay result. As reported: 91.59% (votes for as printed: 68,808,308). View filing ↗
- Section 06, 2021 vote. Form 8-K, filed 2021-11-08. Item 5.07 · say-on-pay result. As reported: 98.26% (votes for as printed: 72,455,802). View filing ↗
- Section 06, 2020 vote. Form 8-K, filed 2020-09-17. Item 5.07 · say-on-pay result. As reported: 77.74% (votes for as printed: 52,028,047). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Myovant Sciences Ltd. (subject), Section 10b CEO total. DEF 14A, filed 2022-07-28. CEO total compensation as printed in Myovant Sciences Ltd.'s own proxy. As printed: 6,247,509. View filing ↗